Aktie 4132 GOLDEN BIOTECHNOLOGY CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Golden Biotechnology Corporation

Aktien

4132

TW0004132006

4132

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 28.06.2024 		% 5 Tage % 1. Jan.
25.1 TWD -1.76% Intraday Chart für Golden Biotechnology Corporation +13.83% -36.05%
29.04. Golden Biotechnology Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
18.01. Golden Biotechnology Corp. stellt die Ergebnisse seiner klinischen Phase II-Studie mit Antroquinonol vor CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
ASCO GI 2024, Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020
Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019
Golden Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 4132 Aktie
  4. Nachrichten Golden Biotechnology Corporation
  5. Andere Sprachen